We are thrilled to announce a significant achievement for our Clinical Investigation Centre (CIC) team! Under the leadership of Assoc. Prof. Dr. Rozita Binti Abdul Malik, the ORIGAMI-3 study has reached a major milestone by enrolling its very first patient in Malaysia.
The study, formally titled “A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy”, explores advanced treatment options for recurrent metastatic colorectal cancer.
This success was made possible through the exceptional efforts of our dedicated team, including Ku Sheau Lee (Kimee), the Study Coordinator, whose meticulous planning and coordination ensured the smooth progress of the trial. Special recognition also goes to Kimee for her prompt updates to the eDC data entry system, showcasing remarkable adaptability and commitment to excellence.
We are proud to contribute to this global research effort and extend our gratitude to the Study Sponsor for their unwavering support. Let’s celebrate this fantastic milestone as we continue to push the boundaries of clinical research together.
article by Hanis Hafizah Ismail
Science Officer, Clinical Investigation Centre
